TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

M Molica, C Mazzone, P Niscola… - Frontiers in oncology, 2021 - frontiersin.org
TP53 is a key tumor suppressor gene with protean functions associated with preservation of
genomic balance, including regulation of cellular senescence, apoptotic pathways …

[HTML][HTML] Recently approved therapies in acute myeloid leukemia: a complex treatment landscape

C Talati, K Sweet - Leukemia research, 2018 - Elsevier
Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for
patients with AML was limited to induction chemotherapy with cytarabine and anthracycline …

The interplay between the genetic and immune landscapes of AML: mechanisms and implications for risk stratification and therapy

LM Mendez, RR Posey, PP Pandolfi - Frontiers in Oncology, 2019 - frontiersin.org
AML holds a unique place in the history of immunotherapy by virtue of being among the first
malignancies in which durable remissions were achieved with “adoptive immunotherapy,” …

Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell …

A Britt, GR Mohyuddin, B McClune, A Singh, T Lin… - Leukemia Research, 2020 - Elsevier
Introduction Chromosome 17 abnormalities, especially disorders of the 17p region and
including TP53 gene mutations, result in very low rates of cure for patients with acute …

Prognosis and treatment in acute myeloid leukemia: a comprehensive review

A Debnath, S Nath - Egyptian Journal of Medical Human Genetics, 2024 - Springer
Acute myeloid leukemia (AML) is a heterogeneous disorder that is characterized by clonal
expansion of immature" blast cells" in the bone marrow and peripheral circulation, resulting …

Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in FLT3, TP53, and MUC4 mutations

E Gholizadeh, E Zangene, A Parsons, M Kontro… - bioRxiv, 2024 - biorxiv.org
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy characterized by
the clonal expansion of myeloid precursor cells. Advances in genomic profiling have …

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients

GR Kamath, D Tremblay, A Coltoff… - Leukemia …, 2019 - pubmed.ncbi.nlm.nih.gov
Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid
leukemia patients Differences in the clinical and genetic profile of Hispanic and non-Hispanic …

Therapeutic targeting of histone H3 lysine 36 trimethylation-deficient cancers

K Lopez - 2019 - ora.ox.ac.uk
Histone modifications play diverse and essential roles in the maintenance of genome
integrity, as evidenced by the frequency at which different histone marks are dysregulated …

Functional characterisation of SLC2A3 and PFKP in t (8; 21)-positive acute myeloid leukemia

A Isa - 2019 - theses.ncl.ac.uk
The translocation t (8; 21) is the most prevalent chromosomal rearrangement in acute
myeloid leukaemia (AML) and results in the expression of the oncogenic fusion protein …